Lyn Baranowski is the COO of Altavant Sciences. She has significant experience in the respiratory therapeutic area leading commercial, transactional, financial and strategic functions. This experience spans roles in multiple biotech companies (Pearl Therapeutics and Melinta Therapeutics), big pharma (Novartis) and venture capital (Vatera Healthcare), giving Ms. Baranowski a unique perspective on how to build and position companies for success. One of the highlights of her career to date has been leading Vatera’s investment in Pearl Therapeutics, a company that she later joined as vice president of commercial development. During her tenure at Pearl, Ms. Baranowski helped build the company and progress its portfolio of COPD drugs prior to its sale to AstraZeneca for $1.15 Billion in 2013. She has an MBA from Harvard Business School and a BA from American University.